Zachariah M. DeFilipp, MD, Massachusetts General Hospital

Articles by Zachariah M. DeFilipp, MD, Massachusetts General Hospital

Treating Chronic Graft-vs-Host Disease

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Shifting Paradigm in Treating Acute Graft-vs-Host Disease

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Graft-vs-Host Disease Prophylaxis Clinical Trials

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Special Transplant Situations

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Risk Factors for Graft-vs-Host Disease

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Overview of Graft-Vs-Host Disease

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Members of the Transplant Team

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Timing of Referral for Transplant

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Joseph H. Antin, MD, Dana-Farber Cancer Institute,Yi-Bin A. Chen, MD, Massachusetts General Hospital,Zachariah M. DeFilipp, MD, Massachusetts General Hospital

June 19th 2020

Clinical Trial Investigation: Where to Go From Here

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

The Future of GvHD: Promising Agents in Development

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

GvHD Management Recommendations

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

REACH2 Trial: Practical Implications and AE Management

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Treatment for Steroid-Refractory GVHD: REACH2

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

When to Initiate Second-Line Therapy

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Second-Line Therapy for GvHD

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

The Role of Steroids in GvHD Management

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Multidisciplinary Treatment and Supportive Care

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

The Importance of Multidisciplinary Approach

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Frontline Agents for GvHD

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

GVHD Grading and Staging

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Risk Factors, Incidence & Typical Presentation of GvHD

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

The Nature of Acute and Chronic GvHD

ByCorey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute,Zachariah M. DeFilipp, MD, Massachusetts General Hospital,Yi-Bin A. Chen, MD, Massachusetts General Hospital

June 11th 2020

Latest Updated Articles

Risk Factors for Graft-vs-Host Disease
June 19th 2020
Risk Factors, Incidence & Typical Presentation of GvHD
June 11th 2020
$Treatment for Steroid-Refractory GVHD: REACH2$
Treatment for Steroid-Refractory GVHD: REACH2
June 11th 2020
Special Transplant Situations
June 19th 2020
GvHD Management Recommendations
June 11th 2020
Members of the Transplant Team
June 19th 2020

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer

Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma

CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma